spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Crohn’s disease 

 HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Dec 2015
Galapagos and Gilead Announce Global Partnership to Develop Filgotinib for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Aug 2015
Virtual Incision Closes $11 Million Equity Financing for First-of-its-Kind Miniaturized Robot for General Surgery
Devices Surgery Venture Capital
 HSMN NewsFeed - 24 Apr 2014
Celgene Acquires Late-Stage Product for Crohn’s Disease and Other Gastrointestinal Disorders
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 29 Jan 2014
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 17 Dec 2013
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe
Biopharmaceuticals
 HSMN NewsFeed - 8 Aug 2013
SetPoint Medical Secures $27 Million Financing, Adding Action Potential Venture Capital/GSK, Boston Scientific and Covidien Ventures as New Investors
Devices Neurology Venture Capital
 HSMN NewsFeed - 18 Dec 2012
Avaxia Biologics Raises $6.4 Million in Series B Financing
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 4 Sep 2012
Revestive(R) (teduglutide) Receives European Marketing Authorization for the Treatment of Adults with Short Bowel Syndrome (SBS)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 Jun 2012
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive(R)) for Patients with Short Bowel Syndrome
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 29 May 2012
Eisai Gains Positive CHMP Opinion for Fycompa(R) (perampanel) First in a New Class of Treatment for Partial Onset Epilepsy
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 11 May 2012
Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 8 Sep 2011
Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 28 Apr 2011
Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2011
Crospon and Smart Medical Systems Sign Collaborative Development Deal
Devices
 HSMN NewsFeed - 31 Jan 2011
GATTEX(R) (teduglutide) Meets Primary Efficacy Endpoint in Phase 3 Pivotal Study in Patients with Adult Short Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Jul 2010
Cytori Gains Stem Cell Device Approval in Europe for Breast Cancer Reconstruction and Soft Tissue Repair
Devices Regenerative Medicine Regulatory
 HSMN NewsFeed - 31 Mar 2010
Eisai Submits Marketing Authorisation Application for Approval of Eribulin Mesylate in Europe, Based on Significant Overall Survival in Late Stage Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Feb 2010
New Study Demonstrates Effectiveness of Prochymal as a Rescue Therapy for Pediatric Patients with Severe Graft vs. Host Disease
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2010
Human Genome Sciences Names Scott Habig Vice President, Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Sep 2009
Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Regenerative Medicine
 HSMN NewsFeed - 10 Sep 2009
Pluristem Begins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Regenerative Medicine
 HSMN NewsFeed - 8 Sep 2009
Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
Biopharmaceuticals
 HSMN NewsFeed - 16 Jun 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Regenerative Medicine
 HSMN NewsFeed - 15 Apr 2009
Resolvyx Appoints Industry Leader Philip Vickers as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2009
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
Regenerative Medicine Cardiology
 HSMN NewsFeed - 15 Jan 2009
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
Regenerative Medicine FDA
 HSMN NewsFeed - 15 Jan 2009
Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product
Regenerative Medicine FDA
 HSMN NewsFeed - 15 Dec 2008
COSMO ANNOUNCES STRATEGIC COLLABORATION WITH SANTARUS FOR U.S. RIGHTS TO BUDESONIDE MMX® AND RIFAMYCIN SV MMX®
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Dec 2008
Osiris Receives Approval for Prochymal Expanded Access Program in Canada
Biopharmaceuticals Regenerative Medicine Regulatory
 HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Aug 2008
Pluristem Appoints Ms. Chaya Mazouz Clinical Operations Director
Regenerative Medicine Personnel
 HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 May 2008
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
Regenerative Medicine FDA
 HSMN NewsFeed - 22 Apr 2008
Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Apr 2008
Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Apr 2008
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Apr 2008
Inotek Focuses Resources on Clinical Programs, Adds to Executive Management Team and Consolidates Operations in Massachusetts
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2008
Salix Acquires Budesonide Products from Dr. Falk Pharma
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Mar 2008
Pfizer Presents New Opportunities for Global Growth
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2008
PanGenetics Raises 23 Million Euro in Series C Financing to Fund Clinical Advancement of Its Therapeutic Antibody Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Biopharmaceuticals FDA Gastroenterology
 HSMN NewsFeed - 7 Jan 2008
Genizon BioSciences Secures $31 Million in Additional Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine
 HSMN NewsFeed - 27 Nov 2007
Cook Medical Delivers Innovative Treatment for Recto-Vaginal Fistulas
Devices
 HSMN NewsFeed - 16 Nov 2007
Argos Therapeutics and Therakos, Inc. Enter Exclusive Agreement for Regulatory T Cell Technology
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Nov 2007
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms Of Ankylosing Spondylitis According to Phase 3 Study Findings
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
Can-Fite: CF101 May Be Effective for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 15 Oct 2007
Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.